ArticleCureus2026
Perianal Crohn Disease in a Patient With Congenital Afibrinogenemia: A Multidisciplinary Therapeutic Management Challenge.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Congenital afibrinogenemia is a rare autosomal recessive coagulation disorder characterized by absent or severely reduced circulating fibrinogen levels, leading to variable hemorrhagic manifestations. The coexistence of congenital afibrinogenemia and Crohn disease is exceptionally rare and represents a major diagnostic and therapeutic challenge, particularly in patients with active fistulizing perianal disease requiring repeated invasive procedures and immunosuppressive therapy. A 20-year-old woman with congenital afibrinogenemia diagnosed during childhood presented with chronic bloody diarrhea and perianal symptoms. Her bleeding history included umbilical cord bleeding, post-vaccination bleeding, recurrent ecchymoses, and fibrinogen levels below 0.4 IU/L. Seven months before admission, she developed a perianal abscess requiring surgical drainage, followed by persistent mucous and bloody diarrhea. Imaging demonstrated inflammatory rectal thickening and an active horseshoe anal fistula. Because of the anticipated hemorrhagic risk associated with endoscopic biopsies, intravenous fibrinogen concentrate was administered before endoscopy. The diagnosis of colonic Crohn disease with active fistulizing perianal involvement was established based on clinical, radiological, endoscopic, and histopathological findings. Following multidisciplinary evaluation, treatment with infliximab and azathioprine was initiated. During follow-up, recurrent epistaxis was successfully controlled with fibrinogen replacement therapy, while gastrointestinal and perianal symptoms markedly improved without major hemorrhagic, thrombotic, or infectious complications. This association of congenital afibrinogenemia with active fistulizing perianal Crohn disease highlights the complexity of balancing inflammatory control, procedural safety, and hemorrhagic risk. Individualized multidisciplinary management and appropriate peri-procedural hemostatic support are essential to optimize outcomes in this exceptionally rare clinical setting.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.